Wave's Duchenne program comes to a screeching halt — now all eyes will be on Huntington's
Wave Life Sciences is folding its hand in Duchene muscular dystrophy after an interim analysis of a Phase I open-label extension trial revealed its lead drug simply does not work.
In addition to discontinuing two trials involving suvodirsen, including a Phase II/III confirmatory trial for the exon 51 skipping therapy, the biotech is also suspending further development of a different molecule designed for patients with mutations amenable to exon 53 skipping.
The implosion triggered a 50% plunge on the stock $WVE, which is trading now at $18.85 — reflecting how, ahead of the bad news, “more than half of the investors’ valuation was DMD” according to Stifel analyst Paul Matteis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.